Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 375 of 494 entries
View as:

BG9928 in Subjects With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT00858156 Org: User:
Start: 04/30/09 End: 08/31/09 Due: 08/31/10

A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage

Phase: N/A Priority: Normal
NCT ID: NCT05106465 Org: User:
Start: 12/15/21 End: 04/03/24 Due: 04/03/25

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00032786 Org: User:
Start: 03/31/02 End: 03/31/04 Due: 03/31/05

Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

Phase: N/A Priority: Normal
NCT ID: NCT01235221 Org: User:
Start: 12/31/10 End: 06/30/12 Due: 06/30/13

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00055367 Org: User:
Start: 04/30/02 End: 05/31/04 Due: 05/31/05

A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

Phase: N/A Priority: Normal
NCT ID: NCT04729907 Org: User:
Start: 04/19/21 End: 07/31/26 Due: 07/31/27

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05127564 Org: User:
Start: 12/03/21 End: 06/29/22 Due: 06/29/23

Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL

Phase: N/A Priority: Normal
NCT ID: NCT00319930 Org: User:
Start: 05/31/05 End: 05/31/07 Due: 05/31/08

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT02106897 Org: User:
Start: 04/30/14 End: 05/24/16 Due: 05/24/17

A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04068532 Org: User:
Start: 11/15/19 End: 11/11/20 Due: 11/11/21

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

Phase: N/A Priority: Normal
NCT ID: NCT02641041 Org: User:
Start: 02/29/16 End: 09/30/16 Due: 09/30/17

BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)

Phase: N/A Priority: Normal
NCT ID: NCT00523328 Org: User:
Start: 08/31/07 End: 10/31/08 Due: 10/31/09

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Phase: N/A Priority: Normal
NCT ID: NCT04241068 Org: User:
Start: 03/02/20 End: 07/22/24 Due: 07/22/25

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

Phase: N/A Priority: Normal
NCT ID: NCT04832399 Org: User:
Start: 11/12/13 End: 10/02/23 Due: 10/02/24

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04593121 Org: User:
Start: 10/30/20 End: 03/05/24 Due: 03/05/25

Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01132703 Org: User:
Start: 01/07/10 End: 05/07/10 Due: 05/07/11

MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study

Phase: N/A Priority: Normal
NCT ID: NCT05058729 Org: User:
Start: 12/07/20 End: 10/08/21 Due: 10/08/22

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

Phase: N/A Priority: Normal
NCT ID: NCT04008186 Org: User:
Start: 06/14/19 End: 08/28/19 Due: 08/28/20

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

Phase: N/A Priority: Normal
NCT ID: NCT02410200 Org: User:
Start: 09/30/15 End: 09/23/16 Due: 09/23/17

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT00083759 Org: User:
Start: 05/31/04 End: - Due: -

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

Phase: N/A Priority: Normal
NCT ID: NCT00707512 Org: User:
Start: 06/30/08 End: 05/28/15 Due: 05/28/16

A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)

Phase: N/A Priority: Normal
NCT ID: NCT04488133 Org: User:
Start: 01/04/21 End: 10/07/25 Due: 10/07/26

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01917019 Org: User:
Start: 08/31/13 End: 03/31/17 Due: 03/31/18

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT02386553 Org: User:
Start: 05/18/15 End: 12/17/24 Due: 12/17/25

Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT01053936 Org: User:
Start: 01/31/10 End: 02/28/11 Due: 02/28/12